Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Neopharma Technologies Announces Strategic Partnership with AusChain to Assist with the Scaling and Global Rollout of NEOVAULT®

PERTH, Australia, Feb. 27, 2025 /PRNewswire/ -- Neopharma Technologies Ltd (Neopharma) is pleased to announce a strategic partnership with AusChain Pty Ltd, a global leader in scalable blockchain solutions specializing in product traceability through QR codes. AusChain has successfully implemente...

2025-02-27 12:01 3662

AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials

Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) HONG KONG, Feb. 27, 2025 /PRNewswire/ -- The stocks in the Hong Kong pharmaceutical sector have ...

2025-02-27 08:00 4641

Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes

* People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles. * Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity and the risk further increases amongst t...

2025-02-26 14:45 2513

Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes

Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025

* Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment * Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission * Safety profile remains c...

2025-02-26 07:45 2798

Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial res...

2025-02-25 18:28 3883

AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.

Another Step Forward in Global Expansion HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines inChina is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announce...

2025-02-25 08:00 2571

3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics

REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ -- 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of agroundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of...

2025-02-24 23:35 2198

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

* Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resi...

2025-02-24 21:00 2279

AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside

HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 23, 2025, announced that the company is fully deploying the DeepSeek large model and promoting the application of DeepSeek R1 version across all business ...

2025-02-24 11:20 3304

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-02-24 07:56 3983

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended31 December 2024. All figures are in AU$ unless stated otherwise. FY2024 highlights * ...

2025-02-20 20:23 4346

BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion

- Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named Chair of the Scientific Advisory Board, joins Board of Directors - Appointment of US-based CEO completes the recent build out of BluMaiden's executive team in preparation for commercialization, supported by COO Dr....

2025-02-19 20:00 2988

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD)cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg). - ASC30 oral once-daily tablet also demonstrated a 4.3% mean body weight reduction fr...

2025-02-19 20:00 4010

TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent to U.S. and European reference Apixaban tablets (Eliquis®) ...

2025-02-17 21:03 3739

3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy

REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as...

2025-02-17 19:25 2492

Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide

RIGA, Latvia, Feb. 17, 2025 /PRNewswire/ -- The leading pharmaceutical company in the Baltics, Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time, Grindeks products will be delivered toPanama. The company's export markets already in...

2025-02-17 15:00 3686

Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2025-02-17 08:00 4073

ASCO GU｜RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer

YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held inSan Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the lates...

2025-02-15 11:02 4962

Duke and Duke-NUS forge new frontiers in climate health research with S$1million funding

* The two institutions awarded more than S$1 million to accelerate five promising areas of research collaboration * Dedicated Research Collaboration Pilot Project grant combines expertise from Singapore and the US for bigger impact * First time in the grant's 15-year history that it focuses e...

2025-02-14 15:18 4254

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

* XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adultpatients with relapsed/refractory multiple myeloma (R/R MM). * After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market in which XPOVIO® has been approved for pu...

2025-02-13 17:30 3920

1 ... 49 50 515253 54 55 ... 184